TL02-59 dihydrochloride

Modify Date: 2024-01-17 21:22:05

TL02-59 dihydrochloride Structure
TL02-59 dihydrochloride structure
Common Name TL02-59 dihydrochloride
CAS Number 2415263-06-6 Molecular Weight 682.56
Density N/A Boiling Point N/A
Molecular Formula C32H36Cl2F3N5O4 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of TL02-59 dihydrochloride


TL02-59 dihydrochloride is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. TL02-59 dihydrochloride inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. TL02-59 dihydrochloride potently suppresses acute myelogenous leukemia (AML) cell growth[1].

 Names

Name TL02-59 dihydrochloride

 TL02-59 dihydrochloride Biological Activity

Description TL02-59 dihydrochloride is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. TL02-59 dihydrochloride inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. TL02-59 dihydrochloride potently suppresses acute myelogenous leukemia (AML) cell growth[1].
Related Catalog
Target

IC50: 0.03 nM (Fgr), 0.1 nM (Lyn) and 160 nM (Hck)[1]

In Vitro TL02-59 dihydrochloride (0.1-1000 nM; 6 hours) potently inhibits Fgr autophosphorylation in TF-1 cells, with paritial inhibition at 0.1-1 nM and complete inhibition above 10 nM. Hck, Lyn and Flt3 are inhibited in the 100 to 1000 nM range[1]. TL02-59 dihydrochloride inhibits the growth and induced apoptosis of AML cell lines expressing this kinase with single-digit nM potency[1]. TL02-59 dihydrochloride induces growth arrest in primary AML bone marrow samples[1]. Western Blot Analysis[1] Cell Line: TF-1 myeloid cells Concentration: 0.1, 1, 10, 100, 1000 nM Incubation Time: 6 hours Result: Inhibited Fgr autophosphorylation in TF-1 cells.
In Vivo TL02-59 (oral; 1 and 10 mg/kg; for three weeks) completely eliminates AML cells from the spleen and peripheral blood in a mouse model of AML, while dramatically suppressing bone marrow involvement[1]. TL02-59 has a t1/2 of 5.7 h by i.v injection and 6.5 h by p.o. administration, respectively[1]. Animal Model: NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice with human MV4-11 AML cells[1] Dosage: 1 and 10 mg/kg Administration: Oral; for three weeks Result: Eliminated AML cells from the spleen and peripheral blood in a mouse model of AML, while dramatically suppressing bone marrow involvement.
References

[1]. Weir MC, et al. Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo. ACS Chem Biol. 2018 Jun 15;13(6):1551-1559.

 Chemical & Physical Properties

Molecular Formula C32H36Cl2F3N5O4
Molecular Weight 682.56